| Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 907 | 2008 |
| Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America SK Gupta, JA Eustace, JA Winston, II Boydstun, TS Ahuja, RA Rodriguez, ... Clinical Infectious Diseases 40 (11), 1559-1585, 2005 | 787 | 2005 |
| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised … JL Lennox, E DeJesus, A Lazzarin, RB Pollard, JVR Madruga, DS Berger, ... The Lancet 374 (9692), 796-806, 2009 | 735 | 2009 |
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 604 | 2008 |
| Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases … GM Lucas, MJ Ross, PG Stock, MG Shlipak, CM Wyatt, SK Gupta, MG Atta, ... Clinical Infectious Diseases 59 (9), e96-e138, 2014 | 357 | 2014 |
| Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor–sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized … JL Lennox, RJ Landovitz, HJ Ribaudo, I Ofotokun, LH Na, C Godfrey, ... Annals of internal medicine 161 (7), 461-471, 2014 | 311 | 2014 |
| Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1–infected patients: final 5-year results from … JK Rockstroh, E DeJesus, JL Lennox, Y Yazdanpanah, MS Saag, H Wan, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 63 (1), 77-85, 2013 | 303 | 2013 |
| Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses JL Lennox, E DeJesus, DS Berger, A Lazzarin, RB Pollard, JVR Madruga, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 39-48, 2010 | 290 | 2010 |
| Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of … RT Steigbigel, DA Cooper, H Teppler, JJ Eron, JM Gatell, PN Kumar, ... Clinical Infectious Diseases 50 (4), 605-612, 2010 | 254 | 2010 |
| Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract CE Hart, JL Lennox, M Pratt-Palmore, TC Wright, RF Schinazi, ... The Journal of infectious diseases 179 (4), 871-882, 1999 | 251 | 1999 |
| A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis PJ Peters, T Harrison, JL Lennox The Lancet infectious diseases 6 (11), 742-748, 2006 | 246 | 2006 |
| HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health CD Pilcher, DC Shugars, SA Fiscus, WC Miller, P Menezes, J Giner, ... Aids 15 (7), 837-845, 2001 | 224 | 2001 |
| Benign symmetric lipomatosis associated with protease inhibitors RL Hengel, NB Watts, JL Lennox The Lancet 350 (9091), 1596, 1997 | 217 | 1997 |
| Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients … JK Rockstroh, JL Lennox, E DeJesus, MS Saag, A Lazzarin, H Wan, ... Clinical infectious diseases 53 (8), 807-816, 2011 | 211 | 2011 |
| Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages K CribbsSushma, M CaliendoAngela, BL Ann, M GuidotDavid AIDS research and human retroviruses, 2015 | 202 | 2015 |
| Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected … DR Feikin, CM Elie, MB Goetz, JL Lennox, GM Carlone, ... Vaccine 20 (3-4), 545-553, 2001 | 186 | 2001 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing RS Gammal, MH Court, CE Haidar, OF Iwuchukwu, AH Gaur, M Alvarellos, ... Clinical Pharmacology & Therapeutics 99 (4), 363-369, 2016 | 181 | 2016 |
| Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines S Kannanganat, BG Kapogiannis, C Ibegbu, L Chennareddi, P Goepfert, ... Journal of virology 81 (21), 12071-12076, 2007 | 173 | 2007 |
| Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials JJ Eron, DA Cooper, RT Steigbigel, B Clotet, JM Gatell, PN Kumar, ... The Lancet Infectious Diseases 13 (7), 587-596, 2013 | 169 | 2013 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy Z Desta, RS Gammal, L Gong, M Whirl‐Carrillo, AH Gaur, C Sukasem, ... Clinical Pharmacology & Therapeutics 106 (4), 726-733, 2019 | 153 | 2019 |
Igho OfotokunProfessor of MedicineVerified email at emory.edu
